CB1 Receptor Antagonist, ATDP 32,456, as an Emergency Treatment Modality for Synthetic Cannabis Overdose in Mice
| dc.creator | Alexander, Brian | |
| dc.creator | Forster, Michael | |
| dc.creator | Nejtek, Vicki | |
| dc.date.accessioned | 2019-08-22T19:38:53Z | |
| dc.date.available | 2019-08-22T19:38:53Z | |
| dc.date.issued | 2015-03 | |
| dc.date.submitted | 2015-02-24T08:29:35-08:00 | |
| dc.description.abstract | ATDP 32, 456 is a proven agent for blocking the effects of cannabinoids at the CB1 receptor. We sought to determine if the suppression of locomotor activity by Delta(9)-THC, JWH-018 and other synthetic cannabinoids could be alleviated with administration of ATDP 32, 456. The suppression of locomotor activity of mice was measured after administration of cannabinoids and after different rescue doses of ATDP 32, 456 given via the intraperitoneal route, 1-hour later. We noted a statistically significant reversal of locomotor activity suppression and inhibition of synthetic cannabinoid effects when mice received 3, 10 or 30 mg/kg ATDP 32, 456. These data support the use of ATDP 32, 456 as an acute treatment method for cannabinoid intoxication, though formulation compatible with intravenous administration would be required for a rapid response. | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12503/26566 | |
| dc.language.iso | en | |
| dc.title | CB1 Receptor Antagonist, ATDP 32,456, as an Emergency Treatment Modality for Synthetic Cannabis Overdose in Mice | |
| dc.type | poster | |
| dc.type.material | text |